EntryPoint Capital’s Foghorn Therapeutics FHTX Stock Holding History

EntryPoint Capital’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75.6K	Buy	+15,483	New	+$68.7K	0.02%	754

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

EntryPoint Capital's FHTX Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Foghorn Therapeutics (FHTX) in Q2 2026: 15,483 shares worth $75.6K. The stake represents 0.02% of the portfolio and ranks #754 among its holdings.

103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

EntryPoint Capital held 15,483 shares of Foghorn Therapeutics worth $75.6K as of Q2 2026.
Foghorn Therapeutics was a new EntryPoint Capital position in Q2 2026.
Foghorn Therapeutics made up 0.02% of EntryPoint Capital's portfolio in Q2 2026, its #754 holding.
103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.